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Purpose/Objectivel: Targeted intraoperative radiation 
therapy (IORT) as an alternative to whole breast irradiation 
has been described for patients with early-stage breast 
cancer. The randomized phase III TARGiT trial demonstrated 
similar recurrence rates to WBI and a lower overall toxicity 
profile on short-term follow-up. We report on our early Latin 
American surgical experience using the Intrabeam 
radiotherapy delivery system. 
Materials and Methods: Prospectively gathered estrogen 
receptor-positive, clinically node-negative patients with 
invasive breast cancer < 2.5 cm receiving using the Intrabeam 
system were reviewed. IORT-related effects and early 
postoperative outcome were assessed.  
Results: Seventy eight patients (median age 67 years) 
underwent lumpectomy, sentinel lymph node biopsy, and 
concurrent IORT from march 2013 to march 2014. Ninety-five 
percent of patients had invasive ductal histology with a 
median tumor size of 1.5 cm.  
Conclusions: While a variety of APBI techniques are currently 
available for clinical use, our early Latin American operative 
experience with IORT shows it is well tolerated with low 
morbidity. The addition of WBI may be necessary in situations 
for positive residual margins or microscopic nodal disease in 
patients who do not undergo additional surgery. 
Implementation of IB impacts treatment planning and 
operating room use in a multidisciplinary breast cancer 
program. The safety profile, ease of administration, and 
reduced costs of IB favor its more widespread use in selected 
patients with early-stage breast cancer. 
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Purpose/Objective: To assess the toxicity of combined 
therapy between external beam radiation therapy (EBRT) 
plus high dose rate brachytherapy (HDRB) as a boost in 
patients with intermediate or high risk prostate cancer. 
Materials and Methods: From 2010 to August 2014, a total of 
221 patients diagnosed as intermediate or high-risk prostate 
cancer were treated with EBRT plus HDRB. Median age was 72 
years (range 52-85). Most patients (68%) were classified as 
high-risk (stage T2c-T3b or PSA >20ng/dl or GS>7), and 70 
patients (32%) were considered intermediate risk. The stage 
of tumor was determined in every case by magnetic 
resonance imaging (MRI). Every patient received first HDRB as 
boost and 4 gold fiducials were implanted. Finally, all 
patients received EBRT by intensity modulated radiotherapy 
technique with imaging guided by CBCT. The patients 
received HDRB as a single 15 Gy implant, followed by EBRT to 
46 Gy in 23 fractions. Thirty seven percent of the high-risk 
patients presented seminal vesicles invasion receiving a 
single 9.5 Gy implant, followed by ERBT to 60 Gy in 30 
fractions. A total of 117 patients (52%) received a dose of 46 
Gy to the true pelvis. In all brachytherapy plans, the 
constraints indicated in the GEC/ESTRO recommendations 
have been respected (Rectum D2cc £75Gy EQD2; Urethra 
D10£ 120Gy EQD2). Most patients (120; 54%) were prescribed 
complete androgen deprivation therapy (ADT), 66 (29%) 
received incomplete ADT and 28 (13%) did not receive ADT. 
GI and GU toxicity was evaluated utilizing the RTOG criteria. 
Median follow-up was 26 months. 
Results: No treatment failure has been observed to the last 
follow-up. The incidences of any acute ≥ Grade 2 GI or GU 
toxicities were 0% and 9% respectively. Dysuria and urgency 
was prevalent symptoms in acute GU toxicity. Late 
genitourinary toxicity included 2 patients (0.9%) with urine 
obstruction requiring intermittent/permanent catheter. One 
case of grade 2 gastrointestinal late toxicity presented 
actinic rectitis event. 
Conclusions: The use of a single 15Gy fraction HDRB as pre-
treatment EBRT boost provides early-term and good 
outcomes in treatment-related toxicity. These data can help 
physicians to assess this scheme of radiotherapy as an 
acceptable option in the prostate carcinoma treatment. 
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Purpose/Objective: APBI is currently considered a viable 
treatment option in early-stage breast cancer patients. 
Mostly due to the rising need to treat patients outside clinical 
trials, in 2009 two consensus statements (CS) were created 
by ASTRO (American Society for Radiation Oncology) and 
GEC-ESTRO (Groupe Européen de Curiethérapie-European 
Society for Radiotherapy and Oncology). More recently, 
guidelines from ABS (American Brachytherapy Society) were 
also published. This helps the train of thought Radiation 
Oncologists have to undergo concerning the decision for the 
most appropriate adjuvant radiation treatment modality in 
early-stage breast cancer patients. Nevertheless, during that 
process, doubts may emerge due to the lack of parallelism 
among the three guidelines that can lead to different risk 
group stratification/treatment indications for the same 
patient. Our study aimed at comparing the rate of suitable 
and unsuitable patients for APBI according to the three 
guidelines. As a secondary objective survival and relapse 
rates were also addressed. 
Materials and Methods: 81 patients submitted to APBI, in a 
single-institution, were retrospectively analyzed (treated 
from 2003 to 2013) and then categorized according to 
indication for treatment as 'suitable', 'cautionary' and 
'unsuitable' (ASTRO), as 'low risk', 'intermediate risk' and 'high 
risk' (GEC-ESTRO), and as 'acceptable' and 'not acceptable' 
(ABS). Data regarding tumour, treatment technique and 
patient-related features was collected, as well as recurrence 
and survival rates. 
Results: Median follow-up time was 35,1 months, 46 patients 
underwent HDR and 35 a PDR technique either with metal 
needles or flexible plastic catheters using a template-based 
system. 75 were suitable for guideline stratification (2 
patients lost to follow-up and 6 without complete 
information about risk factors). According to the ASTRO CS, 
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